Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
The $800,000 DOE grant will be matched by $200,000 from Picasolar. Douglas Hutchings, CEO of both Picasolar and Silicon Solar Solutions, said the SunShot awards are the most prestigious and competitive grants a solar startup can receive.
No matter the situation the world's largest retailer involves itself in, rest assured, it will be analyzed, critiqued and questioned to excruciating levels. The latest area is solar power.
The Arkansas Regional Innovation Hub in North Little Rock and its efforts to foster innovation, entrepreneurship and access to the "knowledge" economy were lauded in the just-released 2014 State of the South report from MDC.
Matt Bakke's idea for an "anti-loyalty" program for businesses and consumers led to the founding Fair Share Data in Bentonville and applying for the ARK Challenge's fall installment in Little Rock.